首页> 外文期刊>Iranian Journal of Reproductive Medicine >COMPARISON BETWEEN TWO METHODS OF OVULATION INDUCTION: CLOMIPHENE ALONE AND CLOMIPHENE +TAMOXIFEN IN PCOS PATIENTS
【24h】

COMPARISON BETWEEN TWO METHODS OF OVULATION INDUCTION: CLOMIPHENE ALONE AND CLOMIPHENE +TAMOXIFEN IN PCOS PATIENTS

机译:两种排卵诱导方法的比较:PCOS患者中单独的克仑苯和克仑苯+他莫昔芬

获取原文
       

摘要

Background: Infertility affects about 10-15% of reproductive-age couples. About half the causes of infertility are female related and approximately 40% of the cases are caused by anovulation, mostly in PCO women.Objective: This study was conducted to determine and compare the effects of two drug treatment regimens: higher dose of clomiphene and a combination of lower dose of clomiphene and tamoxifen in treating infertile women with PCO.Materials and Methods: The study was a randomized clinical trial conducted on 100 infertile patients who referred to Yazd-Iran Infertility Clinic between the years 2001-2003. The patients were selected who had received at least 3 periods of clomiphene, but no pregnancy had occurred. They were randomly divided into two groups. In the first group, clomiphene was increased to 100 mg and the second group 20 mg of tamoxifen was added to 50 mg of clomiphene from day 5-9 of menstruation cycle. Infertility duration, duration of medicine used, PCT score, endometrial thickness, ovulation, and pregnancy rate were studied in both groups.Results: Ovulation rate in clomiphene group was 54.9%; Tamoxifen + clomiphene group was 73.5% without significant differences in both groups. (PV = 0.053). Positive pregnancy rate in clomiphene group was 39.2%; clomiphene + tamoxifen group was 61.2% (P value 0.05), which could be concluded that pregnancy rate was higher in clomiphene/tamoxifen group than in the clomiphene group. The presence of a dominant follicle in the two treatment groups in women between 18-24 was not significant, but in women between 25-39 years was significant (PV= 0.049) (Table III).Conclusion: The recommendation is to add Tamoxifen to Clomiphene in 35-39 women with 20. BMI .26.99 before the use of gonadotropins treatment in PCOS with or without IUI, because these options have higher risk of multiple pregnancy and ovarian hyperstimulation syndrome.
机译:背景:不育症影响约10-15%的育龄夫妇。约有一半的不孕原因与女性有关,约40%的情况是由无排卵引起的,其中多数是在PCO女性中。目的:本研究旨在确定和比较两种药物治疗方案的效果:较高剂量的克罗米芬和阿司匹林材料和方法:这项研究是对2001年至2003年间对100名不育患者进行的一项随机临床试验,该患者转诊至Yazd-Iran不育症诊所。选择接受了至少3次克罗米酚治疗但未发生妊娠的患者。他们被随机分为两组。在第一组中,从月经周期的第5-9天起,克罗米芬增加至100 mg,第二组将20 mg他莫昔芬添加到50 mg克罗米芬中。两组均进行了不孕时间,用药时间,PCT评分,子宫内膜厚度,排卵和妊娠率的研究。结果:克罗米芬组排卵率为54.9%;他莫昔芬+克罗米芬组为73.5%,两组均无显着性差异。 (PV = 0.053)。克罗米芬组的阳性妊娠率为39.2%;克罗米芬+他莫昔芬组为61.2%(P值<0.05),可以推断克罗米芬/他莫昔芬组的妊娠率高于克罗米芬组。在两个治疗组中,年龄在18-24岁之间的女性中占优势的卵泡并不显着,但是在25-39岁之间的女性中则存在显着性卵泡(PV = 0.049)(表III)。结论:建议将他莫昔芬添加到35-39岁女性中的克罗米芬为20。BMI为0.26.99,在有或没有IUI的PCOS中使用促性腺激素治疗之前,因为这些选择有较高的多重妊娠和卵巢过度刺激综合征的风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号